American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint

TAGS

American Regent, Inc., a subsidiary of Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF). Despite a numerical improvement in certain outcomes, the study failed to achieve statistical significance for its primary endpoint. These results may cast a shadow over INJECTAFER’s efficacy in treating subsets of heart failure patients.

Lack of Statistical Significance: A Closer Look at the HEART-FID Data

The HEART-FID trial was uniquely designed as a single pivotal study rather than two, in accordance with a special protocol assessment with the U.S. Food and Drug Administration (FDA). The study focused on a hierarchical composite of death and heart failure hospitalization at 12 months, as well as changes in the 6-minute walk test distance from baseline to 6 months. Although the study revealed numerically fewer deaths and heart failure hospitalizations in the group treated with INJECTAFER compared to the placebo group, it did not meet the pre-specified significance level of 0.0099.

See also  Alliant Insurance Services acquires ASURA Risk in Northern California

Results Discussed at European Society of Cardiology Congress 2023

Data from the failed HEART-FID study were presented in a late-breaking research Hot Line session at the European Society of Cardiology Congress 2023 and simultaneously published in the New England Journal of Medicine. These findings were expected to deepen the understanding of IV iron treatment with ferric carboxymaltose in subsets of patients with heart failure, according to Ravi Tayi, MD, MPH, Chief Medical Officer of American Regent, Inc.

See also  Duke Energy to divest $2bn worth stake in Duke Energy Indiana to GIC

INJECTAFER: A Previously Extensively Studied Intravenous Iron Treatment

INJECTAFER is already extensively studied and approved for treating in adult and pediatric patients, as well as for certain adult patients with heart failure. However, the HEART-FID trial, which is the first of its kind to focus on a composite endpoint of death and heart failure hospitalization, raises questions about the medication’s effectiveness for a wider range of heart failure patients.

See also  Convergint acquires security systems integrator Universal Security Systems

INJECTAFER is manufactured and marketed under the name by outside of North America.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This